You are here

Article Text

Article menu

Download PDFPDF

Miscellaneous
Treatment of advanced NSCLC: promising results with the FTase inhibitor lonafarnib
Free
  1. C Carlin
  1. Clinical Research Fellow, Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow, UK; ccarlin@tiscali.co.uk

https://doi.org/10.1136/thx.2005.la0174

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    ▴ Kim ES, Kies MS, Fosella FV, et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant non-small cell lung carcinoma. Cancer2005;104:561–9
    OpenUrlCrossRefPubMedWeb of Science

    Various cell signalling and centromere proteins whose function is perturbed and/or upregulated in human tumours require the addition of a farnesyl pyrophosphate molecule for normal function. Farnesyl transferase (FTase) inhibitors block this step, reduce the function of these oncogenic proteins, and inhibit the growth of a variety of human tumour cell lines. FTase inhibitors are well …

    View Full Text